Nori Health

What Nori Health does

Nori Health BV, founded in 2017 and headquartered in Utrecht, Netherlands, develops AI-powered chatbot-based digital therapeutics for people living with chronic inflammatory conditions. The core product is a 6-week structured coaching program delivered through a conversational AI coach that maps lifestyle patterns (diet, hydration, medication adherence, stress, sleep) and proactively suggests tailored behavior changes for patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel syndrome (IBS), and rheumatoid arthritis. The platform is built on Google Dialogflow for natural language processing, delivered as a web application with an iPhone mobile companion app, and has been CE-certified as a Class 1 medical device under European Council Directive 93/42/EEC (MDD). Short-term clinical results have been published in a peer-reviewed IBD journal, and the company is currently running the ADJUVANT clinical study in partnership with two Dutch hospitals to further validate therapeutic impact.

The company operates a pure B2B go-to-market with no direct-to-consumer sales channel: Nori Health licenses its digital therapy platform to pharmaceutical companies, hospitals, health systems, and health insurers, who then distribute access codes to patients. Revenue mechanics therefore flow through subscription or licensing arrangements with these enterprise partners, supplemented by clinical trial services (the ADJUVANT study). Customer segments span pharma (seeking adherence and outcomes support alongside medications), hospitals and health systems (extending support between visits), and insurers (managing chronic disease cost-of-care). The company holds an EU Horizon 2020 grant, completed a $670,000 pre-seed round in May 2019, and raised an ~$845,000 seed round in December 2021 led by Healthy.Capital with participation from PharmStars. Co-founders include CEO Roeland Pater (a Crohn's disease patient), registered dietitian Lisa Booth, Business Development Lead Dandyano Zentveld, and Chief Technology Officer Christian Vogel (appointed February 2022).

Name

Nori Health

Legal name

Nori Health BV

Website

https://norihealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Nori Health develops CE-certified AI chatbot digital therapeutics delivering 6-week lifestyle coaching programs for patients with IBD, IBS, and rheumatoid arthritis, licensed B2B to pharmaceutical companies, hospitals, and insurers across Europe.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Other Ambulatory Health Care Services (6219)

SIC

Services-Health Services (8000)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

• Digital therapeutics
• Chronic disease management
• AI chatbot coaching
• Inflammatory bowel disease
• Digital health platform

Headquarters

HQ city

Nieuwegein

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. B2B Licensing/Subscription to Healthcare Partners: The Nori Health program is provided through partners including pharmaceutical companies, insurers, and hospitals who distribute access codes to patients. The company generates revenue by licensing its digital therapy platform to healthcare organizations.
2. Clinical Trial Services: Running clinical trials (ADJUVANT) with hospitals to validate the digital therapy program, which supports both evidence generation and commercial partnerships.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Nori Health provides an AI-powered, chatbot-based digital therapy program delivered as a CE-certified Class 1 medical device for people living with chronic inflammatory conditions including Crohn's Disease, Ulcerative Colitis, IBS, and Rheumatoid Arthritis. The 6-week program delivers evidence-based lifestyle coaching on diet, hydration, medication adherence, stress, and sleep. The platform is licensed to pharmaceutical companies, hospitals, insurers, and research partners who distribute access codes to patients.

Product overview

Nori Health provides evidence-based digital therapies as a single unified product—a chatbot-based digital coach program—for people living with inflammatory conditions including inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel syndrome (IBS), and rheumatoid arthritis (RA). The core product is an AI-powered chatbot that delivers a 6-week coaching program focusing on lifestyle factors such as diet, hydration, stress management, sleep quality, and medication adherence. The company also runs the ADJUVANT clinical study in partnership with hospitals to further validate the digital therapy's impact. Nori Health operates as a B2B company, offering its program through partnerships with pharma companies, hospitals, insurers, and researchers, while also providing direct patient access.

Differentiator

Problem solved

Functional benefit

Products and services

• Nori Health Crohn's & Colitis Digital Therapy Program AI-powered chatbot-based digital therapy program delivering a 6-week evidence-based lifestyle coaching intervention for people with Crohn's Disease and Ulcerative Colitis. Covers diet, hydration, medication adherence, stress, and sleep.
• Nori Health Irritable Bowel Syndrome (IBS) Program Digital therapy program specifically designed for patients with Irritable Bowel Syndrome, providing lifestyle coaching to help manage symptoms and improve daily condition management.
• Nori Health Rheumatoid Arthritis (RA) Program Digital therapy offering for patients with Rheumatoid Arthritis, providing evidence-based lifestyle coaching to improve quality of life and manage symptoms.

Quantifiable outcome

• 28% average improvement in daily condition management after 6-week program
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Multiple Netherlands HospitalscoreStrategic or Co-development Partner · 11 May 2022Partnership with two hospitals in The Netherlands for ADJUVANT clinical study investigating the impact of the digital therapy app on digestive disease patients.
• Primary Care Society for Gastroenterology (PCSG)minorStrategic or Co-development Partner · 2 June 2020UK non-profit initiative supporting free access to the smart chatbot during COVID-19 for vulnerable populations with gastrointestinal conditions.
• Crohn's and Colitis Foundation of the NetherlandscoreStrategic or Co-development Partner · 19 May 2019Conducted a 6-week virtual trial with over 150 patients showing 28% improvement in condition management. Foundation provided validation and patient access for clinical validation of the digital therapy program.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bold Health (formerly Cara Care): Bold Health is a Berlin-based digital therapeutics company focused specifically on gastrointestinal conditions including IBS and IBD, offering app-based programs that combine dietary, psychological, and microbiome coaching — a near-direct competitor to Nori Health's IBD/IBS chatbot coach with similar condition-specific lifestyle focus.
• Mahana Therapeutics: Mahana Therapeutics develops FDA-authorized prescription digital therapeutics for IBS and other chronic conditions, targeting similar gastroenterology patient populations and pursuing a regulated DTx pathway comparable to Nori's CE-marked medical-device positioning.
• Kaia Health: Kaia Health is a digital therapeutics company offering AI-driven, app-based self-management programs for chronic conditions (musculoskeletal pain, COPD) — closely comparable to Nori's chatbot-coach delivery model, condition-specific program structure, and B2B distribution through insurers and employers.
• mySugr (Roche): mySugr is a digital health coaching app for diabetes management, now part of Roche, that combines chatbot-style daily logging with personalized coaching — the same coach-driven, condition-specific, lifestyle-adjacent model Nori uses for chronic bowel disease, and similarly sold into pharma and payer channels.
• Oviva: Oviva is a Europe-based digital health company delivering app- and chat-based lifestyle coaching for chronic conditions (diabetes, obesity, gastrointestinal), reimbursed by European insurers and health systems — a direct competitor in the European DTx reimbursement pathway Nori is targeting.
• Medisafe: Medisafe is a digital medication adherence and chronic condition management platform using personalized digital companions — directly comparable to Nori's chatbot-coach approach to medication adherence and lifestyle support, with similar pharma partnership GTM.

Broad incumbents

• Omada Health: Omada Health is a leading US digital therapeutics company providing virtual care programs for chronic conditions including diabetes, hypertension, and musculoskeletal issues — a broader incumbent in the same DTx category with deeper payer relationships and a larger balance sheet than Nori.
• Hinge Health: Hinge Health is a large digital musculoskeletal therapy platform combining AI-driven exercise coaching with human clinicians, selling to employers and health plans — an adjacent DTx incumbent with similar chatbot-coach DNA and enterprise GTM, but operating at much larger scale in a different condition area.
• Welldoc: Welldoc is an established digital health company offering AI-driven, FDA-cleared chronic disease management platforms (notably diabetes) integrated with health systems and pharma — a broader incumbent in condition-specific digital therapeutics with a regulatory and commercial footprint similar to Nori's ambitions.

Regional players

• Doccla: Doccla is a UK-based virtual care and remote patient monitoring provider working with NHS trusts and European health systems — a regional peer operating in the same European market as Nori with comparable B2B health-system GTM and virtual care delivery model.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/norihealth
• LinkedInlinkedin.com/company/norihealth

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nori Health